Stock Analysts’ updated eps estimates for Wednesday, October 11th: Apogee Therapeutics (NASDAQ:APGE) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $40.00 price target on the stock. B2Gold (NYSEAMERICAN:BTG) (TSE:BTO) was downgraded by analysts at StockNews.com from a strong-buy rating to a buy rating. Donaldson (NYSE:DCI) was upgraded by analysts at […]